Search

Your search keyword '"Suciu, Stefan"' showing total 815 results
Start Over Author "Suciu, Stefan"
815 results on '"Suciu, Stefan"'

1. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

Author

Eggermont, Alexander MM, Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus JM, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Lorigan, Paul, Grebennik, Dmitri, Kreplere, Clemens, Marreaud, Sandrine, Suciu, Stefan, and Robert, Caroline

Published
2024
Full Text
View/download PDF

2. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Author

Efficace, Fabio, Kicinski, Michal, Coens, Corneel, Suciu, Stefan, van der Velden, Walter J. F. M., Noppeney, Richard, Chantepie, Sylvain, Griskevicius, Laimonas, Neubauer, Andreas, Audisio, Ernesta, Luppi, Mario, Fuhrmann, Stephan, Foà, Robin, Crysandt, Martina, Gaidano, Gianluca, Vrhovac, Radovan, Venditti, Adriano, Posthuma, Eduardus F. M., Candoni, Anna, Baron, Frédéric, Legrand, Olivier, Mengarelli, Andrea, Fazi, Paola, Vignetti, Marco, Giraut, Anne, Wijermans, Pierre W., Huls, Gerwin, and Lübbert, Michael

Published
2024
Full Text
View/download PDF

3. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Author

Kennedy, Oliver John, Glassee, Nina, Kicinski, Michal, Blank, Christian U., Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Giacomo, Anna Maria Di, van den Eertwegh, Alfonsus J.M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Gandini, Sara, Buhrer, Emanuel, Suciu, Stefan, Robert, Caroline, Eggermont, Alexander M.M., Mandala, Mario, Lorigan, Paul, and Valpione, Sara

Published
2024
Full Text
View/download PDF

4. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, de Jonge-Peeters, Susan Dorothé, Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, and Huls, Gerwin

Published
2023
Full Text
View/download PDF

5. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Author

Kennedy, Oliver John, Kicinski, Michal, Valpione, Sara, Gandini, Sara, Suciu, Stefan, Blank, Christian U., Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J.M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Robert, Caroline, Eggermont, Alexander M.M., Lorigan, Paul, and Mandala, Mario

Published
2023
Full Text
View/download PDF

6. Results of the prospective EORTC Children Leukemia Group study 58081 in precursor B‐ and T‐cell acute lymphoblastic leukemia.

Author

Domenech, Carine, Kicinski, Michal, De Moerloose, Barbara, Piette, Caroline, Chahla, Wadih A., Kornreich, Laure, Pasquet, Marlène, Uyttebroeck, Anne, Theron, Alexandre, Poirée, Marilyne, Arfeuille, Chloé, Bakkus, Marleen, Grardel, Nathalie, Paillard, Catherine, Freycon, Claire, Millot, Frédéric, Simon, Pauline, Philippet, Pierre, Pluchart, Claire, and Suciu, Stefan

Published
2024
Full Text
View/download PDF

7. Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial

Author

Efficace, Fabio, primary, Kicinski, Michal, additional, Coens, Corneel, additional, Suciu, Stefan, additional, van der Velden, Walter J.F.M, additional, Noppeney, Richard, additional, Chantepie, Sylvain P, additional, Griskevicius, Laimonas, additional, Neubauer, Andreas, additional, Audisio, Ernesta, additional, Luppi, Mario, additional, Fuhrmann, Stephan, additional, Foà, Robin, additional, Crysandt, Martina, additional, Gaidano, Gianluca, additional, Vrhovac, Radovan, additional, Venditti, Adriano, additional, Posthuma, Eduardus F.M., additional, Candoni, Anna, additional, Baron, Frédéric, additional, Legrand, Olivier, additional, Mengarelli, Andrea, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Giraut, Anne, additional, Wijermans, Pierre W., additional, Huls, Gerwin A, additional, and Lübbert, Michael, additional

Published
2024
Full Text
View/download PDF

8. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Lesimple, Thierry, Maio, Michele, Linette, Gerald, Mortier, Laurent, Svane, Inge Marie, Schachter, Jacob, Brown, Michael, Hersey, Peter, Barrow, Catherine, Kudchadkar, Ragini, Dutriaux, Caroline, Song, Xinni, Quaglino, Pietro, Queirolo, Paola, Meier, Friedegund, Stroyakovskiy, Daniil, Guillot, Bernard, Romero, Pablo Luis Ortiz, Bastholt, Lars, Garbe, Claus, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Loquai, Carmen, Meiss, Frank, Chiarion Sileni, Vanna, Bar-Sela, Gil, Fitzharris, Bernard, Saiag, Philippe, Arnault, Jean-Philippe, Simon, Jan-Christoph, Stephens, Rosalie, Baurain, Jean-Francois, Lebbe, Célèste, Combemale, Patrick, Dummer, Reinhard, Hauschild, Axel, Parente, Phillip, Yamazaki, Naoya, Milhem, Mohammed, Leccia, Marie-Thérèse, Geoffrois, Lionel, Kretschmer, Lutz, Dunwoodie, Elaine, Walker, John, Lotem, Michal, Hendler, Daniel, Mackiewicz, Andrzej, Sekulovic, Lidija, Dzienis, Marcin, Hospers, Geke A.P., Siano, Marco, Hassel, Jessica, Corrie, Philippa, Passos, Maria-Jose, Levin, Max, Hoeller, Christoph, Machet, Laurent, Hallmeyer, Sigrun, Waterston, Ashita, Descamps, Vincent, Kiecker, Felix, Aarts, Maureen, Schmidt, Henrik, Raimundo, Ana, Nyakas, Marta, Lacour, Jean-Philippe, Berking, Carola, Ferrucci, Pier Francesco, Jameson, Michael, Kim, Kevin, Yokota, Kenji, Kerger, Joseph, Aubin, François, Groenewegen, Gerard, Kapiteijn, Helena, Boehncke, Wolf-Henning, Utikal, Jochen, Casasola, Richard, Marshall, Ernest, Ferraresi, Virginia, Richtig, Erika, Matkovic, Suzana, Inozume, Takashi, Crook, Timothy, McNeil, Catriona, Kiyohara, Yoshio, Avril, Marie-Francoise, Hein, Rüdiger, Terheyden, Patrick, Nathan, Paul, Aoi, Jun, Skytta, Tanja, Jouary, Thomas, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Bottomley, Andrew, Coens, Corneel, Mierzynska, Justyna, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Puig, Susana, Ascierto, Paolo A, Larkin, James, Lorigan, Paul C, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, Robert, Caroline, and Eggermont, Alexander M M

Published
2021
Full Text
View/download PDF

9. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Author

Menzies, Alex, Lesimple, Thierry, Maio, Michele, Linette, Gerald, Brown, Michael, Hersey, Peter, Svane, Inge Marie, Mortier, Laurent, Schachter, Jacob, Barrow, Catherine, Kudchadkar, Ragini, Song, Xinni, Dutriaux, Caroline, Quaglino, Pietro, Meier, Friedegund, Queirolo, Paola, Stroyakovskiy, Daniil, Bastholt, Lars, Guillot, Bernard, Garbe, Claus, Ortiz Romero, Pablo Luis, Grange, Florent, Mohr, Peter, Algazi, Alain, Bechter, Oliver, Hernberg, Micaela, Arnault, Jean-Philippe, Saiag, Philippe, Loquai, Carmen, Meiss, Frank, Simon, Jan-Christoph, Bar-Sela, Gil, Chiarion Sileni, Vanna, Fitzharris, Bernard, McCrystal, Mike, Parente, Phillip, Baurain, Jean-Francois, Combemale, Patrick, Lebbe, Célèste, Hauschild, Axel, Yamazaki, Naoya, Dummer, Reinhard, Milhem, Mohammed, Dzienis, Marcin, Walker, John, Geoffrois, Lionel, Leccia, Marie-Thérèse, Kretschmer, Lutz, Hendler, Daniel, Lotem, Michal, Mackiewicz, Andrzej, Sekulovic, Lidija, Dunwoodie, Elaine, Hoeller, Christoph, Machet, Laurent, Hassel, Jessica, Hospers, Geke A.P., Passos, Maria-Jose, Levin, Max, Fehr, Martin, Corrie, Philippa, Waterston, Ashita, Hallmeyer, Sigrun, Schmidt, Henrik, Descamps, Vincent, Lacour, Jean-Philippe, Berking, Carola, Kiecker, Felix, Ferrucci, Pier Francesco, Yokota, Kenji, Aarts, Maureen, Jameson, Michael, Winge-Main, Anna Katharina, Ferreira, Paula, Kim, Kevin, McNeil, Catriona, Hofmann-Wellenhof, Reiner, Kerger, Joseph, Aubin, François, Utikal, Jochen, Ferraresi, Virginia, Inozume, Takashi, Kiyohara, Yoshio, Groenewegen, Gerard, Kapiteijn, Helena, Matkovic, Suzana, Boehncke, Wolf-Henning, Casasola, Richard, Crook, Timothy, Marshall, Ernest, Skytta, Tanja, Avril, Marie-Francoise, Jouary, Thomas, Hein, Rüdiger, Terheyden, Patrick, Aoi, Jun, Takenouchi, Tatsuya, Straume, Oddbjorn, Martins, César, Mukhametshina, Guzel, Nathan, Paul, Eggermont, Alexander M M, Blank, Christian U, Mandalà, Mario, Long, Georgina V, Atkinson, Victoria G, Dalle, Stéphane, Haydon, Andrew M, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S, Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A, Rutkowski, Piotr, Schadendorf, Dirk, Koornstra, Rutger, Hernandez-Aya, Leonel, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J M, Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, Lorigan, Paul C, van Akkooi, Alexander C J, Krepler, Clemens, Ibrahim, Nageatte, Marreaud, Sandrine, Kicinski, Michal, Suciu, Stefan, and Robert, Caroline

Published
2021
Full Text
View/download PDF

10. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Author

MS Hematologie, Kennedy, Oliver John, Glassee, Nina, Kicinski, Michal, Blank, Christian U., Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Giacomo, Anna Maria Di, van den Eertwegh, Alfonsus J.M., Grob, Jean Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Gandini, Sara, Buhrer, Emanuel, Suciu, Stefan, Robert, Caroline, Center München, Munich, Germany, Comprehensive, Mandala, Mario, Lorigan, Paul, Valpione, Sara, MS Hematologie, Kennedy, Oliver John, Glassee, Nina, Kicinski, Michal, Blank, Christian U., Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Giacomo, Anna Maria Di, van den Eertwegh, Alfonsus J.M., Grob, Jean Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Gandini, Sara, Buhrer, Emanuel, Suciu, Stefan, Robert, Caroline, Center München, Munich, Germany, Comprehensive, Mandala, Mario, Lorigan, Paul, and Valpione, Sara

Published
2024

11. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

Author

MS Hematologie, Eggermont, Alexander MM, Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus JM, Grob, Jean Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Lorigan, Paul, Grebennik, Dmitri, Kreplere, Clemens, Marreaud, Sandrine, Suciu, Stefan, Robert, Caroline, MS Hematologie, Eggermont, Alexander MM, Kicinski, Michal, Blank, Christian U., Mandala, Mario, Long, Georgina V., Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus JM, Grob, Jean Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C.J., Lorigan, Paul, Grebennik, Dmitri, Kreplere, Clemens, Marreaud, Sandrine, Suciu, Stefan, and Robert, Caroline

Published
2024

12. Long-term neurotoxicity among childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC Children Leukemia Group studies

Author

de Ville de Goyet, Maëlle, Kicinski, Michal, Suciu, Stefan, Vandecruys, Els, Uyttebroeck, Anne, Ferster, Alina, Freycon, Claire, Plat, Geneviève, Thomas, Caroline, Barbati, Mélissa, Dresse, Marie-Françoise, Paillard, Catherine, Pluchart, Claire, Simon, Pauline, Chantrain, Christophe, Minckes, Odile, van der Werff Ten Bosch, Jutte, Bertrand, Yves, Rohrlich, Pierre, Millot, Frédéric, Paulus, Robert, Benoît, Yves, Piette, Caroline, de Ville de Goyet, Maëlle, Kicinski, Michal, Suciu, Stefan, Vandecruys, Els, Uyttebroeck, Anne, Ferster, Alina, Freycon, Claire, Plat, Geneviève, Thomas, Caroline, Barbati, Mélissa, Dresse, Marie-Françoise, Paillard, Catherine, Pluchart, Claire, Simon, Pauline, Chantrain, Christophe, Minckes, Odile, van der Werff Ten Bosch, Jutte, Bertrand, Yves, Rohrlich, Pierre, Millot, Frédéric, Paulus, Robert, Benoît, Yves, and Piette, Caroline

Abstract

Survival after childhood acute lymphoblastic leukemia (ALL) has increased over the last 40 years with an overall survival above 90%. Survivors may experience neurological late effects secondary to chemotherapy and radiotherapy. This observational retrospective study evaluated the cumulative incidence of neurological late effects among 890 childhood ALL survivors treated in EORTC CLG trials (58741, 58831/2 and 58881) between 1971 and 1998. Median follow-up was 19 years and interquartile range of the follow-up was 15–22 years. At 20 years from the end of treatment, approximately 66% of patients from the 58741 trial (accrual time: 1971–1978) and approximately 15% from the more recent trials had cognitive disturbance grade 1 or higher. Cumulative incidences at 20 years from treatment end of seizures, stroke and leukoencephalopathy were respectively 45%, 16% and 62% in study 58741, 13%, 2% and 5% in study 58831/2, and 8%, 2% and 3% in study 58881. Patients who were 10–17 years of age at diagnosis had a higher incidence of stroke and leukoencephalopathy as compared to those less than 6 years of age. Noteworthy, all neurological late effects continued to occur beyond 5 years after end of treatment. This retrospective study highlights the frequency of neurological late effects in survivors of childhood ALL. With the increase of the overall survival of ALL patients, the role and potential benefit of longitudinal neurological screening should be evaluated in further studies as these neurological late effects become an important public health challenge. This study is part of the larger EORTC CLG 58 Late Adverse Effects (LAE) study (ClinicalTrials.gov Identifier NCT01298388, date of registration February 16, 2011)., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2024

13. Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long‐term follow‐up of the EORTC‐GIMEMA randomized AML‐10 trial

Author

Baron, Frédéric, primary, Efficace, Fabio, additional, Cannella, Laura, additional, Stevens‐Kroef, Marian, additional, Amadori, Sergio, additional, de Witte, Theo, additional, Lübbert, Michael, additional, Venditti, Adriano, additional, and Suciu, Stefan, additional

Published
2024
Full Text
View/download PDF

15. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

Author

Bufalino, Rosaria, Cameron, David, Cascinelli, Natale, Doherty, Valerie, Eggermont, Alexander, Garbe, Claus, Gore, Martin, Hancock, Barry, Harrison, Rebecca, Ives, Natalie, Kirkwood, John, Kressig, Michael, Lee, Sandra, Lorigan, Paul, MacKie, Rona, Markovic, Svetomir N., Marsden, Jerry, Suciu, Stefan, Suman, Vera, Turner, Lesley, Wheatley, Keith, Ives, Natalie J., and Eggermont, Alexander M.M.

Published
2017
Full Text
View/download PDF

16. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

Author

Coens, Corneel, Suciu, Stefan, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D, Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A, Richards, Jon M, Lebbé, Celeste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S, Maio, Michele, Bottomley, Andrew, Kotapati, Srividya, de Pril, Veerle, Testori, Alessandro, and Eggermont, Alexander M M

Published
2017
Full Text
View/download PDF

17. Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

Author

Baron, Frédéric, Stevens-Kroef, Marian, Kicinski, Michal, Meloni, Giovanna, Muus, Petra, Marie, Jean-Pierre, Halkes, Constantijn J. M., Thomas, Xavier, Vrhovac, Radovan, Specchia, Giorgina, Lefrere, Sr, Francois, Sica, Simona, Mancini, Marco, Venditti, Adriano, Hagemeijer, Anne, Becker, Heiko, Jansen, Joop H., Amadori, Sergio, de Witte, Theo, Willemze, Roelof, and Suciu, Stefan

Published
2018
Full Text
View/download PDF

18. Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Author

Kennedy, Oliver John, primary, Kicinski, Michal, additional, Valpione, Sara, additional, Gandini, Sara, additional, Suciu, Stefan, additional, Blank, Christian U., additional, Long, Georgina V., additional, Atkinson, Victoria G., additional, Dalle, Stéphane, additional, Haydon, Andrew M., additional, Meshcheryakov, Andrey, additional, Khattak, Adnan, additional, Carlino, Matteo S., additional, Sandhu, Shahneen, additional, Larkin, James, additional, Puig, Susana, additional, Ascierto, Paolo A., additional, Rutkowski, Piotr, additional, Schadendorf, Dirk, additional, Boers-Sonderen, Marye, additional, Di Giacomo, Anna Maria, additional, van den Eertwegh, Alfonsus J.M., additional, Grob, Jean-Jacques, additional, Gutzmer, Ralf, additional, Jamal, Rahima, additional, van Akkooi, Alexander C.J., additional, Robert, Caroline, additional, Eggermont, Alexander M.M., additional, Lorigan, Paul, additional, and Mandala, Mario, additional

Published
2023
Full Text
View/download PDF

19. Prognostic and predictive value of metformin in the European organisation for research and treatment of cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Author

Kennedy, Oliver J., Kicinski, Michal, Valpione, Sara, Gandini, Sara, Suciu, Stefan, Blank, Christian U., Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna M., van der Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C. J., Robert, Caroline, Eggermont, Alexander M. M., Lorigan, Paul, Mandala, Mario, Kennedy, Oliver J., Kicinski, Michal, Valpione, Sara, Gandini, Sara, Suciu, Stefan, Blank, Christian U., Long, Georgina V., Atkinson, Victoria G., Dalle, Stéphane, Haydon, Andrew M., Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna M., van der Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C. J., Robert, Caroline, Eggermont, Alexander M. M., Lorigan, Paul, and Mandala, Mario

Abstract

Background: Metformin is a commonly prescribed and well-tolerated medication. In laboratory studies, metformin suppresses BRAF wild-type melanoma cells but accelerates the growth of BRAF-mutated cells. This study investigated the prognostic and predictive value of metformin, including with respect to BRAF mutation status, in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial. Methods: Patients with resected high-risk stage IIIA, IIIB, or IIIC melanoma received 200 mg of pembrolizumab (n = 514) or placebo (n = 505) every 3 weeks for twelve months. Pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) at approximately 42 months median follow-up (Eggermont et al., TLO, 2021). Multivariable Cox regression was used to estimate associations of metformin with RFS and DMFS. Interaction terms were used to model effect modification by treatment and BRAF mutation. Results: Fifty-four patients (0.5%) used metformin at baseline. Metformin was not significantly associated with RFS (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.52–1.45) and DMFS (HR 0.82, 95% CI 0.47–1.44). The interaction between metformin and the treatment arm was not significant for either RFS (p = 0.92) or DMFS (p = 0.93). Among patients with mutated BRAF, the association of metformin with RFS (HR 0.70, 95% CI 0.37–1.33) was greater in magnitude though not significantly different to those without mutated BRAF (HR 0.98, 95% CI 0.56–1.69). Conclusions: There was no significant impact of metformin use on pembrolizumab efficacy in resected high-risk stage III melanoma. However, larger studies or pooled analyses are needed, particularly to explore a possible effect of metformin in BRAF-mutated melanoma. © 2023

Published
2023

21. The prognostic value of IKZF1plus in B‐cell progenitor acute lymphoblastic leukemia: Results from the EORTC 58951 trial

Author

Kicinski, Michal, primary, Arfeuille, Chloé, additional, Grardel, Nathalie, additional, Bakkus, Marleen, additional, Caye‐Eude, Aurélie, additional, Plat, Geneviève, additional, Ferster, Alina, additional, Uyttebroeck, Anne, additional, De Moerloose, Barbara, additional, Rohrlich, Pierre, additional, Suciu, Stefan, additional, Bertrand, Yves, additional, and Cavé, Hélène, additional

Published
2023
Full Text
View/download PDF

22. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Author

Eggermont, Alexander M M, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D, Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A, Richards, Jon M, Lebbé, Céleste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S, Maio, Michele, Konto, Cyril, Hoos, Axel, de Pril, Veerle, Gurunath, Ravichandra Karra, de Schaetzen, Gaetan, Suciu, Stefan, and Testori, Alessandro

Published
2015
Full Text
View/download PDF

23. Quality of Life of Long‐term childhood Acute Lymphoblastic Leukemia survivors: Comparison with healthy controls

Author

Chantziara, Sofia, Musoro, Jammbe, Rowsell, Alison C., Sleurs, Charlotte, Coens, Corneel, Pe, Madeline, Suciu, Stefan, Kicinski, Michal, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie‐françoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, Van Der Werff Ten Bosch, Jutte, Rohrlich, Pierre, Benoit, Yves, Darlington, Anne‐sophie, Piette, Caroline, And On Behalf Of The European Organisation For Research, and Group (clg, Treatment Of Cancer (eortc) Quality Of Life (qlg) And Childr

Abstract

Objective: Improved treatment landscape has led to better outcomes for paediatric acute lymphoblastic leukemia (ALL) survivors. As the number of survivors increase, we need to elucidate the long-term quality of life (QoL) and domains of complaints in these patients. Furthermore, the main priorities of these patients need to be clarified. We assessed long-term QoL outcomes of survivors of childhood ALL compared to matched population controls.Methods: QoL data were collected from survivors recruited in France and Belgium between 2012 and 2017, including the Short Form Health Survey (SF-12) and the Quality of Life Systemic Inventory (QLSI). The Wilcoxon test was used to compare SF-12 scale scores between survivors and matched population controls. For the QLSI, comparisons were mainly descriptive.Results: one hundred and eighty-six survivors (mean age: 27.6 years; range: 18.1–52.8) at follow-up completed QoL measures, amongst whom 180 were matched to controls. Overall, survivors had higher QoL on all SF12 scale scores, indicating that they had better functioning compared to controls. Statistically significant differences on the SF12 were observed for Vitality, Social Functioning, Role Limitations due to Emotional Problems and Mental Health scales. QLSI outcomes suggested that survivors were happier than controls with Couple and Social Relations. Controls were unhappiest compared to survivors with Money, Love life, Self-esteem, Nutrition and Paid Work.Conclusions: our findings suggest that survivors of childhood ALL have better QoL outcomes on some domains compared to the general population, specifically around social and emotional functioning, and that they tend to prioritize their relationships more. Interventions for improving QoL outcomes, might build on existing positive experiences with family, friends and partners.

Published
2022

24. 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Author

Efficace, Fabio, primary, Huls, Gerwin A., additional, Kicinski, Michal, additional, Van Der Velden, Walter JFM, additional, Noppeney, Richard, additional, Chantepie, Sylvain, additional, Griskevicius, Laimonas, additional, Neubauer, Andreas, additional, Audisio, Ernesta, additional, Luppi, Mario, additional, Fuhrmann, Stephan, additional, Foà, Robin, additional, Crysandt, Martina, additional, Gaidano, Gianluca, additional, Vrhovac, Radovan, additional, Venditti, Adriano, additional, Posthuma, Eduardus F.M., additional, Candoni, Anna, additional, Baron, Frederic, additional, Legrand, Olivier, additional, Mengarelli, Andrea, additional, Vignetti, Marco, additional, Giraut, Anne, additional, Coens, Corneel, additional, Suciu, Stefan, additional, Wijermans, P.W., additional, and Luebbert, Michael, additional

Published
2022
Full Text
View/download PDF

25. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma

Author

Eggermont, Alexander M.M., primary, Kicinski, Michal, additional, Blank, Christian U., additional, Mandala, Mario, additional, Long, Georgina V., additional, Atkinson, Victoria, additional, Dalle, Stéphane, additional, Haydon, Andrew, additional, Meshcheryakov, Andrey, additional, Khattak, Adnan, additional, Carlino, Matteo S., additional, Sandhu, Shahneen, additional, Larkin, James, additional, Puig, Susana, additional, Ascierto, Paolo A., additional, Rutkowski, Piotr, additional, Schadendorf, Dirk, additional, Boers-Sonderen, Marye, additional, Di Giacomo, Anna Maria, additional, van den Eertwegh, Alfonsus J.M., additional, Grob, Jean-Jacques, additional, Gutzmer, Ralf, additional, Jamal, Rahima, additional, van Akkooi, Alexander C.J., additional, Lorigan, Paul, additional, Grebennik, Dmitri, additional, Krepler, Clemens, additional, Marreaud, Sandrine, additional, Suciu, Stefan, additional, and Robert, Caroline, additional

Published
2022
Full Text
View/download PDF

26. Socio-economic outcomes among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies: Results of the 58LAE study

Author

European Organisation for Research and Treatment of Cancer (EORTC) Children's Leukemia Group (CLG), Barbati, Melissa, Kicinski, Michal, Suciu, Stefan, Mazingue, Françoise, Vandecruys, Els, Plat, Geneviève, Uyttebroeck, Anne, Paillard, Catherine, Dresse, Marie-Françoise, Simon, Pauline, Pluchart, Claire, Minckes, Odile, Ferster, Alina, Freycon, Claire, Millot, Frederic, Van Der Werff Ten Bosch, Jutte, Chantrain, Christophe, Paulus, Robert, de Schaetzen, Gaetan, Rossi, Giovanna, Rohrlich, Pierre, Benoit, Yves, Piette, Caroline, Brussels Heritage Lab, and Growth and Development

Subjects
Adult, Employment, Marital Status, hematology, oncology, Humans, Pediatrics, Perinatology, and Child Health, Survivors, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cranial Irradiation, Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
Abstract

OBJECTIVE: The objective of this study is to evaluate the socio-economic outcomes of survivors of childhood acute lymphoblastic leukaemia (ALL). METHODS: Childhood ALL adult survivors, enrolled in EORTC trials between 1971 and 1998 in France and Belgium, were invited to fill out a questionnaire with information about their socio-economic situation (living with a partner, having a university degree, having a job, working part time and history of having a paid job). The outcomes were compared with two matched control populations. RESULTS: Among 1418 eligible patients, 507 (35.8%) participated, including 39 (8%) and 61 (12%) patients who received a haematopoietic stem cell transplantation (HSCT) and a cranial radiotherapy (CRT), respectively. The median time to follow-up was 20 years, and median age was 25 years. Survivors showed a socio-economic level at least as good as controls. HCST and CRT were associated with a higher probability of not obtaining a bachelor degree (respectively OR = 3.49, 95% CI: 1.46-8.35 and OR = 2.31, 95% CI: 1.04-5.15), HSCT was associated with unemployment (OR = 2.89, 95% CI: 1.09-7.65) and having a relapse was associated with a higher probability of not having a partner (OR = 1.88, 95% CI: 1.01-3.51) adjusting for confounders. CONCLUSION: Childhood ALL survivors showed a high level of socio-economic participation. HCST and CRT were associated with poorer functioning.

Published
2022

27. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Author

Lübbert, Michael, Wijermans, Pierre W, Kicinski, Michal, Chantepie, Sylvain, Van der Velden, Walter J F M, Noppeney, Richard, Griškevičius, Laimonas, Neubauer, Andreas, Crysandt, Martina, Vrhovac, Radovan, Luppi, Mario, Fuhrmann, Stephan, Audisio, Ernesta, Candoni, Anna, Legrand, Olivier, Foà, Robin, Gaidano, Gianluca, van Lammeren-Venema, Danielle, Posthuma, Eduardus F M, Hoogendoorn, Mels, Giraut, Anne, Stevens-Kroef, Marian, Jansen, Joop H, de Graaf, Aniek O, Efficace, Fabio, Ammatuna, Emanuele, Vilque, Jean-Pierre, Wäsch, Ralph, Becker, Heiko, Blijlevens, Nicole, Dührsen, Ulrich, Baron, Frédéric, Suciu, Stefan, Amadori, Sergio, Venditti, Adriano, Huls, Gerwin, Finke, Jürgen, Schaap, Nicolaas Petrus Michael, Zucenka, Andrius, Metzelder, Stephan, Jost, Edgar, Perić, Zinaida, Forghieri, Fabio, Allione, Bernadino, Martelli, Maurizio, Iori, Anna Paola, Wittnebel, Sebastian, Mengarelli, Andrea, Imovilli, Annalisa, Olivieri, Attilio, De Prijck, Bernard José Marie, van der Poel, Marjolein W.M., Junghanß, Christian, Salih, Helmut Rainer, Tafuri, Agostino, Guimarães, José Eduardo, Musso, Maurizio, De Fabritiis, Paolo, Chevallier, Patrice, Selleslag, Dominik Luc, Cascavilla, Nicola, Berneman, Zwi, Jaspers, Aurélie, Zuffa, Eliana, Vanstraelen, Gaëtan, Visani, Giuseppe, Cuijpers, Maria Louisa Henriëtte, De Becker, Ann, Mianulli, Anna Maria, Hackanson, Björn, Mihaylov, Georgi Georgiev, Martinelli, Giovanni, Paolini, Stefania, Zinzani, Pier Luigi, Henkes, Martin, Al-Ali, Haifa Kathrin, La Rosée, Paul, Chierichini, Anna, Cudillo, Laura, Specchia, Giorgina, Šimec, Njetočka Gredelj, Capalbo, Silvana Franca, Spinosa, Giuseppina, Molica, Stefano, and de Jonge-Peeters, Susan Dorothé

Abstract

Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy with decitabine monotherapy could improve outcomes.

Published
2023
Full Text
View/download PDF

28. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group

Author

Lübbert, Michael, Suciu, Stefan, Hagemeijer, Anne, Rüter, Björn, Platzbecker, Uwe, Giagounidis, Aristoteles, Selleslag, Dominik, Labar, Boris, Germing, Ulrich, Salih, Helmut R., Muus, Petra, Pflüger, Karl-Heinz, Schaefer, Hans-Eckart, Bogatyreva, Lioudmila, Aul, Carlo, de Witte, Theo, Ganser, Arnold, Becker, Heiko, Huls, Gerwin, van der Helm, Lieke, Vellenga, Edo, Baron, Frédéric, Marie, Jean-Pierre, Wijermans, Pierre W., and on behalf of the EORTC Leukemia Group and the German MDS Study Group

Published
2016
Full Text
View/download PDF

29. Different outcome of T cell acute lymphoblastic leukemia with translocation t(11;14) treated in two consecutive children leukemia group EORTC trials

Author

Simon, Pauline, Suciu, Stefan, Clappier, Emmanuelle, Cave, Hélène, Sirvent, Nicolas, Plat, Geneviève, Thyss, Antoine, Mechinaud, Françoise, Costa, Vitor M., Ferster, Alina, Lutz, Patrick, Mazingue, Françoise, Plantaz, Dominique, Plouvier, Emmanuel, Bertrand, Yves, Benoit, Yves, Dastugue, Nicole, Rohrlich, Pierre S., and on behalf of the Children’s Leukemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC)

Published
2016
Full Text
View/download PDF

30. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results

Author

Dastugue, Nicole, Suciu, Stefan, Plat, Geneviève, Speleman, Frank, Cavé, Hélène, Girard, Sandrine, Bakkus, Marleen, Pagès, Marie Pierre, Yakouben, Karima, Nelken, Brigitte, Uyttebroeck, Anne, Gervais, Carine, Lutz, Patrick, Teixeira, Manuel R., Heimann, Pierre, Ferster, Alice, Rohrlich, Pierre, Collonge, Marie Agnès, Munzer, Martine, Luquet, Isabelle, Boutard, Patrick, Sirvent, Nicolas, Karrasch, Matthias, Bertrand, Yves, and Benoit, Yves

Published
2013
Full Text
View/download PDF

31. Prognostic and predictive value of beta-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Author

Kennedy, Oliver J., Kicinski, Michal, Valpione, Sara, Gandini, Sara, Suciu, Stefan, Blank, C.U., Koornstra, R.H., Lorigan, P.C., Mandala, M., Kennedy, Oliver J., Kicinski, Michal, Valpione, Sara, Gandini, Sara, Suciu, Stefan, Blank, C.U., Koornstra, R.H., Lorigan, P.C., and Mandala, M.

Abstract

Item does not contain fulltext

Published
2022

32. Quality of life of long-term childhood acute lymphoblastic leukemia survivors: Comparison with healthy controls

Author

European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLG) and Children's Leukemia Group (CLG), Chantziara, Sofia, Musoro, Jammbe, Rowsell, Alison C, Sleurs, Charlotte, Coens, Corneel, Pe, Madeline, Suciu, Stefan, Kicinski, Michal, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie-Françoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, Bosch, Jutte Van Der Werff Ten, Rohrlich, Pierre, Benoit, Yves, Darlington, Anne-Sophie, Piette, Caroline, European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLG) and Children's Leukemia Group (CLG), Chantziara, Sofia, Musoro, Jammbe, Rowsell, Alison C, Sleurs, Charlotte, Coens, Corneel, Pe, Madeline, Suciu, Stefan, Kicinski, Michal, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie-Françoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, Bosch, Jutte Van Der Werff Ten, Rohrlich, Pierre, Benoit, Yves, Darlington, Anne-Sophie, and Piette, Caroline

Abstract

Objective: Improved treatment landscape has led to better outcomes for paediatric acute lymphoblastic leukemia (ALL) survivors. As the number of survivors increase, we need to elucidate the long-term quality of life (QoL) and domains of complaints in these patients. Furthermore, the main priorities of these patients need to be clarified. We assessed long-term QoL outcomes of survivors of childhood ALL compared to matched population controls.Methods: QoL data were collected from survivors recruited in France and Belgium between 2012 and 2017, including the Short Form Health Survey (SF-12) and the Quality of Life Systemic Inventory (QLSI). The Wilcoxon test was used to compare SF-12 scale scores between survivors and matched population controls. For the QLSI, comparisons were mainly descriptive.Results: One hundred and eighty-six survivors (mean age: 27.6 years; range: 18.1-52.8) at follow-up completed QoL measures, amongst whom 180 were matched to controls. Overall, survivors had higher QoL on all SF12 scale scores, indicating that they had better functioning compared to controls. Statistically significant differences on the SF12 were observed for Vitality, Social Functioning, Role Limitations due to Emotional Problems and Mental Health scales. QLSI outcomes suggested that survivors were happier than controls with Couple and Social Relations. Controls were unhappiest compared to survivors with Money, Love life, Self-esteem, Nutrition and Paid Work.Conclusions: Our findings suggest that survivors of childhood ALL have better QoL outcomes on some domains compared to the general population, specifically around social and emotional functioning, and that they tend to prioritize their relationships more. Interventions for improving QoL outcomes, might build on existing positive experiences with family, friends and partners.

Published
2022

33. Sociodemographic and medical determinants of quality of life in long-term childhood acute lymphoblastic leukemia survivors enrolled in EORTC CLG studies

Author

European Organisation Res Treatme, Childrens Leukemia Grp CLG, Sleurs, Charlotte, Musoro, Jammbe, Rowsell, Ali, Kicinski, Michal, Suciu, Stefan, Chantziara, Sofia, Coens, Corneel, Pe, Madeline, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie-Francoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, ten Bosch, Jutte van der Werff, Rohrlich, Pierre-Simon, Benoit, Yves, Darlington, Anne-Sophie, Piette, Caroline, European Organisation Res Treatme, Childrens Leukemia Grp CLG, Sleurs, Charlotte, Musoro, Jammbe, Rowsell, Ali, Kicinski, Michal, Suciu, Stefan, Chantziara, Sofia, Coens, Corneel, Pe, Madeline, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie-Francoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, ten Bosch, Jutte van der Werff, Rohrlich, Pierre-Simon, Benoit, Yves, Darlington, Anne-Sophie, and Piette, Caroline

Abstract

Simple Summary Long-term quality of life and its potential risk factors in childhood acute lymphoblastic leukemia (ALL) patients remain uncertain. In this cross-sectional study, we investigated daily life quality and life challenges in adult survivors of ALL using multiple self-report questionnaires. Furthermore, risk factors, including gender, age at diagnosis, relapse/second neoplasm, risk group, and cranial radiotherapy, were explored in detail. Younger, female, and relapsed patients appeared to encounter more life challenges, while physical challenges occurred more often in relapsed and high-risk patients. More positive effects on socializing were found in the older patients compared to younger patients. This study provides important information for individual and specialized support. Background: due to increasing survival rates in childhood acute lymphoblastic leukemia (ALL), the number of survivors has been expanding. A significant proportion of these survivors can experience long-term emotional and psychosocial problems. However, the exact risk factors remain inconclusive. We investigated potential risk factors for decreased daily life quality and life challenges in long-term childhood ALL survivors enrolled between 1971 and 1998 in EORTC studies. Methods: self-report questionnaires were collected from 186 survivors (109 females; mean age at diagnosis 5.62 years, range 0.2-14.7; median time since diagnosis of 20.5 years (12.9-41.6)), including the Short-Form Health Survey (SF-12) and Impact of Cancer-Childhood Survivors (IOC-CS). Multivariable linear regression models were used to assess the impact of gender, age at diagnosis, relapse/second neoplasm, National Cancer Institute (NCI) risk group and cranial radiotherapy on 2 subscales of the SF-12 (physical and mental health) and five subscales of the IOC-CS (life challenges, body and health, personal growth, thinking and memory problems and socializing). Results: mental component scores of SF-12 were not si

Published
2022

34. Sociodemographic and medical determinants of quality of life in long-term childhood acute lymphoblastic leukemia survivors enrolled in eortc clg studies

Author

Sleurs, Charlotte, Musoro, Jammbe, Rowsell, Ali, Kicinski, Michal, Suciu, Stefan, Chantziara, Sofia, Coens, Corneel, Pe, Madeline, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie-Françoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, Ten Bosch, Jutte van der Werff J.v.d.W., Rohrlich, Pierre, Benoît, Yves, Darlington, Anne Sophie, Piette, Caroline, Sleurs, Charlotte, Musoro, Jammbe, Rowsell, Ali, Kicinski, Michal, Suciu, Stefan, Chantziara, Sofia, Coens, Corneel, Pe, Madeline, Missotten, Pierre, Vandecruys, Els, Uyttebroeck, Anne, Dresse, Marie-Françoise, Pluchart, Claire, Ferster, Alina, Freycon, Claire, Ten Bosch, Jutte van der Werff J.v.d.W., Rohrlich, Pierre, Benoît, Yves, Darlington, Anne Sophie, and Piette, Caroline

Abstract

Background: due to increasing survival rates in childhood acute lymphoblastic leukemia (ALL), the number of survivors has been expanding. A significant proportion of these survivors can experience long-term emotional and psychosocial problems. However, the exact risk factors remain inconclusive. We investigated potential risk factors for decreased daily life quality and life challenges in long-term childhood ALL survivors enrolled between 1971 and 1998 in EORTC studies. Methods: self-report questionnaires were collected from 186 survivors (109 females; mean age at diagnosis 5.62 years, range 0.2–14.7; median time since diagnosis of 20.5 years (12.9–41.6)), including the Short-Form Health Survey (SF-12) and Impact of Cancer-Childhood Survivors (IOC-CS). Multivariable linear regression models were used to assess the impact of gender, age at diagnosis, relapse/second neoplasm, National Cancer Institute (NCI) risk group and cranial radiotherapy on 2 subscales of the SF-12 (physical and mental health) and five subscales of the IOC-CS (life challenges, body and health, personal growth, thinking and memory problems and socializing). Results: mental component scores of SF-12 were not significantly associated with any risk factor. Physical component scores were lower in relapsed, irradiated and NCI high-risk patients. Regarding IOC-CS negative impact subscales, life challenges was more negatively impacted by cancer in female, younger (i.e. <6 years) and relapsed patients. Regarding the positive impact scales, personal growth was more positively impacted in relapsed patients, whereas body and health, and socializing, were less positively impacted in these patients, compared to non-relapsed patients. Socializing was more positively impacted in older patients (>6 years). Conclusions: this study demonstrates that long-term outcomes can be both adverse and positive, depending on the patient’s demographic and clinical characteristics. Younger, female, and relapsed patients might e, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

38. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)

Author

Becker, Heiko, Suciu, Stefan, Rüter, Björn Hans, Platzbecker, Uwe, Giagounidis, Aristoteles, Selleslag, Dominik, Labar, Boris, Germing, Ulrich, Salih, Helmut R., Muus, Petra, Pflüger, Karl-Heinz, Hagemeijer, Anne, Schaefer, Hans-Eckart, Fiaccadori, Valeria, Baron, Frédéric, Ganser, Arnold, Aul, Carlo, de Witte, Theo, Wijermans, Pierre W., and Lübbert, Michael

Published
2015
Full Text
View/download PDF

40. Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

Author

Oosterveld, Margriet, Suciu, Stefan, Muus, Petra, Germing, Ulrich, Delforge, Michel, Belhabri, Amin, Aul, Carlo, Selleslag, Dominik, Ferrant, Augustin, Marie, Jean-Pierre, Amadori, Sergio, Jehn, Ulrich, Mandelli, Franco, Hess, Uwe, Hellström-Lindberg, Eva, Cakmak-Wollgast, Songuel, Vignetti, Marco, Labar, Boris, Willemze, Roel, and de Witte, Theo

Published
2015
Full Text
View/download PDF

41. EORTC Melanoma Group achievements

Author

Testori, Alessandro, Suciu, Stefan, van Akkooi, Alexander C.J., Cook, Martin, Ghanem, Ghanem, Karra Gurunath, R., Keilholz, Ulrich, van Kempen, Leon, Leyvraz, Serge, Mihm, Martin, Newton-Bishop, Julia, Patel, Poulam, Robert, Caroline, Schadendorf, Dirk, de Schaetzen, Gaetan, Spatz, Alan, de Vries, Esther, and Eggermont, Alexander M.M.

Published
2012
Full Text
View/download PDF

42. EORTC Leukemia Group achievements

Author

Willemze, Roel, Suciu, Stefan, Marie, Jean-Pierre, Karrasch, Matthias, Jansen, Joop, Amadori, Sergio, Muus, Petra, Labar, Boris, Baron, Frédéric, Selleslag, Dominik, Wijermans, Pierre, Bron, Dominique, Hagemeijer, Ann, Meloni, Giovanna, Lübbert, Michael, and de Witte, Theo

Published
2012
Full Text
View/download PDF

45. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

Author

Kennedy, Oliver J., primary, Kicinski, Michal, additional, Valpione, Sara, additional, Gandini, Sara, additional, Suciu, Stefan, additional, Blank, Christian U., additional, Long, Georgina V., additional, Atkinson, Victoria G., additional, Dalle, Stéphane, additional, Haydon, Andrew M., additional, Meshcheryakov, Andrey, additional, Khattak, Adnan, additional, Carlino, Matteo S., additional, Sandhu, Shahneen, additional, Larkin, James, additional, Puig, Susana, additional, Ascierto, Paolo A., additional, Rutkowski, Piotr, additional, Schadendorf, Dirk, additional, Koornstra, Rutger, additional, Hernandez-Aya, Leonel, additional, Di Giacomo, Anna M., additional, van den Eertwegh, Alfonsus J.M., additional, Grob, Jean-Jacques, additional, Gutzmer, Ralf, additional, Jamal, Rahima, additional, van Akkooi, Alexander C.J., additional, Robert, Caroline, additional, Eggermont, Alexander M.M., additional, Lorigan, Paul, additional, and Mandala, Mario, additional

Published
2022
Full Text
View/download PDF

46. Fertility Status Among Long-Term Childhood Acute Lymphoblastic Leukaemia Survivors Enrolled Between 1971 and 1998 in EORTC CLG Studies: Results of the 58 Late Adverse Effects Study

Author

Rossi, Giovanna, primary, Kicinski, Michal, additional, Suciu, Stefan, additional, Vandecruys, Els, additional, Plat, Geneviève, additional, Uyttebroeck, Anne, additional, Paillard, Catherine, additional, Barbati, Mélissa, additional, Dresse, Marie-Françoise, additional, Simon, Pauline, additional, Minckes, Odile, additional, Pluchart, Claire, additional, Ferster, Alina, additional, Freycon, Claire, additional, Millot, Frederic, additional, van der Werff ten Bosch, Jutte, additional, Chantrain, Christophe, additional, Paulus, Robert, additional, de Rojas, Teresa, additional, de Schaetzen, Gaetan, additional, Rohrlich, Pierre, additional, Benoit, Yves, additional, and Piette, Caroline, additional

Published
2022
Full Text
View/download PDF

48. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial

Author

Aslanyan, Mariam G., Kroeze, Leonie I., Langemeijer, Saskia M. C., Koorenhof-Scheele, Theresia N., Massop, Marion, van Hoogen, Patricia, Stevens-Linders, Ellen, van de Locht, Louis T., Tönnissen, Evelyn, van der Heijden, Adrian, da Silva-Coelho, Pedro, Cilloni, Daniela, Saglio, Giuseppe, Marie, Jean-Pierre, Tang, Ruoping, Labar, Boris, Amadori, Sergio, Muus, Petra, Willemze, Roel, Marijt, Erik W. A., de Witte, Theo, van der Reijden, Bert A., Suciu, Stefan, and Jansen, Joop H.

Published
2014
Full Text
View/download PDF

49. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Author

De Moerloose, Barbara, Suciu, Stefan, Bertrand, Yves, Mazingue, Françoise, Robert, Alain, Uyttebroeck, Anne, Yakouben, Karima, Ferster, Alice, Margueritte, Geneviève, Lutz, Patrick, Munzer, Martine, Sirvent, Nicolas, Norton, Lucilia, Boutard, Patrick, Plantaz, Dominique, Millot, Frederic, Philippet, Pierre, Baila, Liliana, Benoit, Yves, and Otten, Jacques

Published
2010
Full Text
View/download PDF

50. Sociodemographic and Medical Determinants of Quality of Life in Long-Term Childhood Acute Lymphoblastic Leukemia Survivors Enrolled in EORTC CLG Studies

Author

Sleurs, Charlotte, primary, Musoro, Jammbe, additional, Rowsell, Ali, additional, Kicinski, Michal, additional, Suciu, Stefan, additional, Chantziara, Sofia, additional, Coens, Corneel, additional, Pe, Madeline, additional, Missotten, Pierre, additional, Vandecruys, Els, additional, Uyttebroeck, Anne, additional, Dresse, Marie-Françoise, additional, Pluchart, Claire, additional, Ferster, Alina, additional, Freycon, Claire, additional, van der Werff ten Bosch, Jutte, additional, Rohrlich, Pierre-Simon, additional, Benoit, Yves, additional, Darlington, Anne-Sophie, additional, and Piette, Caroline, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results